Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
TPO receptor agonist treatment for severe persistent cytopenia associated with CAR-T therapy resulted in complete cytopenia remission among most patients.
Researchers sought to determine whether higher doses of tisagenlecleucel would improve survival outcomes among pediatric patients with relapsed/refractory B-ALL.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.
Researchers sought to determine whether tisagenlecleucel would be safe and effective in patients with primary central nervous system lymphoma.
Long-term data from 62 of 69 patients in a single-phase 2 trial to determine the efficacy of a combination of anti-BCMA and anti-CD19 CAR-T therapies are presented.
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Researchers sought to determine whether tisagenlecleucel is safe and effective in patients younger than 3 years old with relapsed/refractory ALL.
